Krebspatienten sollten bei zweiter COVID-Impfung Vorrang haben

Monin L et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncology 2021; https://doi.org/10.1016/S1470-2045(21)00213-8

Palich R et al. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Annals of Oncology 2021; https://doi.org/10.1016/j.annonc.2021.04.020

Barrière J et al. Impaired immunogenicity of BNT162b2 anti SARS-CoV-2 vaccine in patients treated for solid tumors. Annals of Oncology 2021; https://doi.org/10.1016/j.annonc.2021.04.019